Dr Reddy’s ties up with RDIF for Corona vaccine Sputnik V
The Russian Direct Investment Fund (RDIF) has tied up with India’s Dr. Reddy’s Laboratories to conduct the clinical trials of Sputnik V vaccine in India.
If the vaccine gets approved from the Indian regulators, Russia will supply 100 million doses of the Covid-19 vaccine. As per a MINT report, deliveries could begin as early as December this year.
“India is among the most severely impacted countries from covid-19, and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against covid-19,” RDIF chief executive officer Kirill Dmitriev was quoted as saying by the report.
Also read: Dr. Reddy’s expands portfolio with acquisition of ANDA in US
The development comes at a time when India has become second worst affected country after the United States as Covid-19 tally has crossed 5 million mark. The average number of daily cases stands at around 90,000.
Responding to the development, G V Prasad, CEO Dr Reddy’s, was quoted as saying, “The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.”
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
